Colin La Galia is a highly experienced executive in phamaceuticals, health care, devices and diagnostics, as well as business development locally and internationally.
Mr La Galia has been the managing director of NeuroSpine Institute since June 2023. Prior to that, he was the senior business advisor and general manager for Australia at InstaMed, chief commercial officer at technology firm DUG, and chief executive of Epichem from October 2019 to March 2022. He was also the regional business director and commercial head of Asia Pacific, China and Japan for Abbott Rapid Diagnostics; and held senior roles for over 20 years at Alere, Origin Healthcare, Hollywood Fertility Centre, GlaxoSmithKline and Merck Sharpe & Dohme.
Mr La Galia has been a board member of Neurospine Foundation, Avon Recovery Centre, and The Hospital Research Foundation Group. He has also been an advisory panel chair for biotech company Meliorem and STEM education service provider StemSmart, an independent expert on the Government’s ARC Panel, and a foundational committee member of Lifesciences WA.
